Interazioni tra farmaci
Allogeneic cultured keratinocytes / fibroblasts in bovine collagen + Bacitracin-neomycin-polymyxin
Gravità: Maggiore
Allogeneic cultured keratinocytes / fibroblasts in bovine collagen and Bacitracin-neomycin-polymyxin: major interaction.
Ultimo aggiornamento
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
Sintesi
Topical antibiotics applied to a wound can degrade or damage the living cultured cell construct. This may reduce the graft's viability and therapeutic effect.
Cosa significa questa interazione in parole semplici
Allogeneic cultured keratinocytes / fibroblasts in bovine collagen and Bacitracin-neomycin-polymyxin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Perché avviene
Direct cytotoxic effect of topical antibiotics on the cultured cells at the wound site.
Cosa fare
Do not apply the antibiotic ointment to the site before the graft. If exposed, irrigate the wound thoroughly with saline and allow a washout period before application.
Cosa chiedere al farmacista
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per sbloccare le indicazioni complete sulla gestione di Allogeneic cultured keratinocytes / fibroblasts in bovine collagen e Bacitracin-neomycin-polymyxin, le note aggiuntive, il dettaglio delle evidenze e il controllo delle interazioni per un'intera prescrizione.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altre interazioni di Bacitracin-neomycin-polymyxin
- Atracurium + Bacitracin-neomycin-polymyxin Maggiore
- Bacitracin-neomycin-polymyxin + Capreomycin Maggiore
- Bacitracin-neomycin-polymyxin + Cidofovir Maggiore
- Bacitracin-neomycin-polymyxin + Cisatracurium Maggiore
- Bacitracin-neomycin-polymyxin + Pancuronium Maggiore
- Bacitracin-neomycin-polymyxin + Rocuronium Maggiore
Domande frequenti
Can I take Allogeneic cultured keratinocytes / fibroblasts in bovine collagen with Bacitracin-neomycin-polymyxin?
MediHelp rates the interaction as major. Allogeneic cultured keratinocytes / fibroblasts in bovine collagen and Bacitracin-neomycin-polymyxin can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Topical antibiotics applied to a wound can degrade or damage the living cultured cell construct. This may reduce the graft's viability and therapeutic effect.
How serious is the interaction between Allogeneic cultured keratinocytes / fibroblasts in bovine collagen and Bacitracin-neomycin-polymyxin?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Do not apply the antibiotic ointment to the site before the graft. If exposed, irrigate the wound thoroughly with saline and allow a washout period before application.
What other medicines interact with Bacitracin-neomycin-polymyxin?
MediHelp also lists interactions of Bacitracin-neomycin-polymyxin with, for example, Atracurium, Capreomycin, Cidofovir. The full list is on the Bacitracin-neomycin-polymyxin page.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
